Abstract
Patients with Alzheimer disease (AD) face a cruel paradox when it comes to clinical trials: the moment that people are the most eager to enroll in treatment protocols, they may least be able to decide for themselves whether participation is appropriate. The resulting inability to recruit volunteers for vitally needed research can slow or even stifle the development of new methods to combat AD at a moment when scientists are becoming increasingly optimistic about creating effective disease-modifying treatments. What if a …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
